Clinical trials: Sars-CoV-2
Post-COVID-19 Syndrome, Fatigue Syndrome, Chronic
REGAIN: RCT of Oxaloacetate for Fatigue in Long COVID
Following acute COVID-19, some patients develop a group of debilitating symptoms that include fatigue, orthostatic intolerance, difficulty with attention and concentration (often called "brain fog"), myalgias and disrupted sleep.
- Trial name
- NCT05840237
- Testing
- Anhydrous Enol-Oxaloacetate, a "Medical Food", White Rice Flour
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Terra Biological LLC
Post COVID Syndrome Long Covid, Post COVID Syndrome
Whole-Body Electrostimulation for Functional Recovery in Post-COVID Syndrome
Post-COVID syndrome is a condition that affects some people after recovering from the acute phase of COVID-19. Common symptoms include persistent fatigue, reduced physical capacity, and difficulties performing everyday…
- Conditions
- Post COVID Syndrome Long Covid, Post COVID Syndrome, Long COVID Fatigue, Long Covid
- Trial name
- WB-EMS PostCOV (NCT07312357)
- Testing
- Whole-Body Electromyostimulation Suit
- Volunteers
- 30 people
- Sponsor
- Universidad Rey Juan Carlos
COVID-19
Prospective Evaluation of SARS-CoV-2 Antibodies Levels in a Vaccinated Population of Valle de Aburra
Recent research evidence shows that levels of antibodies acquierd post vacunation against SARS-Cov-2 decrease over time as well as the efficacy to control the infection, additionally in a multicenter study carried out in 2020…
- Trial name
- NCT05172167
- Testing
- Levels of IgG and IgM SARS-CoV-2 antibodies blood test., RT-PCR SARS-CoV-2 nasopharyngeal swab
- Where
- Colombia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Universidad de Antioquia
COVID-19, SARS-CoV-2 Infection
COVID-19: SARS-CoV-2 Specific Memory B and T-CD4+ Cells
The current pandemic caused by the newly identified coronavirus responsible for COVID-19 is a major threat to our populations and societies.
- Trial name
- MEMO-COV2 (NCT04402892)
- Testing
- 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (hospitalized Patients ), 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (cured Patients)
- Volunteers
- 60 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
COVID-19
CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)
There is currently no treatment available for COVID-19, the acute respiratory illness caused by the novel SAR-CoV-2. Convalescent plasma from patients who have recovered from COVID-19 that contains antibodies to the virus is a…
- Trial name
- CONCOR-1 (NCT04348656)
- Testing
- Convalescent plasma
- Where
- 73 sites in United States, Brazil and 1 more
- Volunteers
- 940 people
- Sponsor
- Hamilton Health Sciences Corporation
Covid19, Coronavirus Infection
TranSfUsion of coNvalescent plAsma for the Early Treatment of pneuMonIa in COVID-19 Patients
This is a multicenter open-label randomized study for the early treatment of pneumonia due to SARS-COV2 with transfusion of convalescent plasma.
- Conditions
- Covid19, Coronavirus Infection, Pneumonia, Viral
- Trial name
- NCT04716556
- Testing
- Convalescent plasma
- Where
- 48 sites in Italy
- Volunteers
- 474 people
- Sponsor
- Istituto Superiore di Sanità
Colorectal Carcinoma, COVID 19
Impact of the COVID-19 Pandemic on Oncologic Outcomes in Colorectal Cancer
The goal of this observational study is to assess the impact of the COVID-19 pandemic on colorectal cancer (CRC) outcomes, particularly focusing on stage distribution and recurrence-free survival in patients undergoing surgery at…
- Trial name
- NCT06638957
- Where
- South Korea
- Volunteers
- 14,951 people
- Sponsor
- In Ja Park
COVID-19
Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years
This is a Phase 2/3 randomized, observer-blinded, placebo-controlled, age de-escalation trial to evaluate the safety and immunogenicity of 2 primary doses of SARS-CoV-2 rS with Matrix-M™ adjuvant (NVX-CoV2373) given 21 days apart…
- Trial name
- COVID-19 (NCT05468736)
- Testing
- SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)
- Where
- 94 sites in United States, Colombia and 8 more
- Volunteers
- 3,600 people, healthy volunteers welcome
- Sponsor
- Novavax
Neuro-PASC, Long COVID
Immune-mediated Pathogenic Mechanisms of Neuro-PASC in Veterans
Mental health symptoms, including cognitive impairment ("brain fog"), following COVID-19 are of great concern to Veterans. This research seeks to advance understanding of the long-term effects of COVID-19 on neuropsychiatric and…
- Trial name
- PASC (NCT06932237)
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- VA Office of Research and Development
Healthy
Convalescent Plasma Donor Vaccine Study An Observational Antibody Level Study.
There is a need to understand antibody responses following SARS-COV-2 infection and subsequent vaccination.
- Trial name
- C-VELVET (NCT04954937)
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- NHS Blood and Transplant
Long COVID-19, Post-COVID-19 Syndrome
Exercise and Post-COVID/ Long-COVID: Effects of Different Training Modalities on Various Parameters in People Affected by the Sequelae of COVID-19
The current COVID-19 pandemic is the most severe health crisis of the 21st century. This is not only due to the deaths caused by the disease.
- Conditions
- Long COVID-19, Post-COVID-19 Syndrome, COVID-19
- Trial name
- NCT05204511
- Testing
- endurance training, concurrent training
- Where
- Austria
- Volunteers
- 66 people
- Sponsor
- University of Vienna
Corona Virus Infection, SARS-CoV Infection
Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)
Study Objective: To test if early preemptive hydroxychloroquine therapy can prevent disease progression in persons with known symptomatic COVID-19 disease, decreasing hospitalizations and symptom severity.
- Conditions
- Corona Virus Infection, SARS-CoV Infection, Coronavirus
- Trial name
- NCT04421664
- Testing
- Hydroxychloroquine
- Where
- 8 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
COVID 19
Impact of COVID-19 on Personal Protection Among Dentist in Egypt
Dentist exposed to coronavirus (COVID-19) may not have adequate access to personal protective equipment (PPE), safety procedures, and diagnostic protocols.
- Trial name
- NCT04403828
- Testing
- Survey
- Where
- Egypt
- Volunteers
- 323 people
- Sponsor
- Fayoum University
SARS-CoV 2, Neurologic Manifestations
COVID19 Neurological Manifestation
This study is a prospective observational cohort study to document the prevalence and types of neurological manifestations among hospitalized patients with confirmed or suspected novel coronavirus infection (COVID-19).
- Trial name
- NCT04496128
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of Pittsburgh
COVID
COVID-19 Impact on Rheumatic Patients
A study to assess the impact of coronavirus disease 2019 (COVID-19) pandemic on the attitude, behaviour and mental health of rheumatic patients and to compare them with healthy individuals.
- Trial name
- NCT04407299
- Testing
- self-administered structured questionnaire
- Where
- Egypt
- Volunteers
- 360 people
- Sponsor
- Cairo University
COVID-19 Pandemic, COVID-19 Vaccines
UNAIR Inactivated COVID-19 Vaccine INAVAC as Heterologue Booster (Immunobridging Study) in Adolescent Subjects
This is an open label trial. There will only be 1 group in the study. All subjects will receive INAVAC vaccine and be followed for 6 months. The vaccine will be administered intramuscularly.
- Trial name
- NCT06272253
- Testing
- INAVAC (Vaksin Merah Putih - UA- SARS CoV-2 (Vero Cell Inactivated) 5 μg
- Where
- Indonesia
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Dr. Soetomo General Hospital
Covid-19
Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients
To evaluate the safety and efficacy of antroquinonol treatment of mild to moderate pneumonia due to COVID-19, as measured by the proportion of patients alive and free of respiratory failure.
- Trial name
- NCT04523181
- Testing
- Antroquinonol
- Where
- 15 sites in United States, Argentina and 1 more
- Volunteers
- 124 people
- Sponsor
- Golden Biotechnology Corporation
COVID-19
Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019
The purpose of this study is to evaluate the efficacy and safety of favipiravir combined with tocilizumab in the treatment of corona virus disease 2019.
- Trial name
- NCT04310228
- Testing
- Favipiravir Combined With Tocilizumab, Favipiravir, Tocilizumab
- Where
- 6 sites in China
- Volunteers
- 150 people
- Sponsor
- Peking University First Hospital
SARS-COV2, Severe Acute Respiratory Syndrome
Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2
The goal of this study is to evaluate if CT (Computerized Tomography) can effectively and accurately predict disease progression in patients with SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2).
- Conditions
- SARS-COV2, Severe Acute Respiratory Syndrome, COVID-19
- Trial name
- NCT04320511
- Testing
- CT-V
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Corewell Health East
Long COVID
Prospective, Open-label Study of Seraph 100 in Patients With Prolonged COVID (PC)
This study will use a prospective, open, single-arm design, in which a group of 100 patients with a diagnosis of prolonged COVID, previously selected according to inclusion and exclusion criteria, and who have undergone informed…
- Trial name
- NCT06637800
- Testing
- Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100)
- Where
- Mexico
- Sponsor
- ExThera Medical Corporation